ANTGX
Price
$11.10
Change
-$0.00 (-0.00%)
Updated
Jun 2 closing price
Net Assets
551.01M
VIHAX
Price
$48.62
Change
+$0.31 (+0.64%)
Updated
Jun 2 closing price
Net Assets
19.99B
Interact to see
Advertisement

ANTGX vs VIHAX

Header iconANTGX vs VIHAX Comparison
Open Charts ANTGX vs VIHAXBanner chart's image
ANTGX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
ANTGX vs. VIHAX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTGX is a Hold and VIHAX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 20B vs. ANTGX (551M). ANTGX pays higher dividends than VIHAX: ANTGX (4.60) vs VIHAX (3.40). ANTGX was incepted earlier than VIHAX: ANTGX (7 years) vs VIHAX (10 years). ANTGX (0.83) is less costly to investors than VIHAX (0.16). ANTGX is a more actively managed with annual turnover of: 71.00 vs. VIHAX (9.00). ANTGX has a lower initial minimum investment than VIHAX: ANTGX (0) vs VIHAX (3000). VIHAX annual gain was more profitable for investors over the last year : 26.29 vs. ANTGX (18.40). VIHAX return over 5 years is better than : 50.19 vs. ANTGX (25.04).
ANTGXVIHAXANTGX / VIHAX
Total Expense Ratio0.030.1619%
Annual Report Gross Expense Ratio0.830.16519%
Fund Existence7 years10 years-
Gain YTD7.87211.25070%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets551M20B3%
Annual Yield % from dividends4.603.40135%
Returns for 1 year18.4026.2970%
Returns for 3 years28.4964.4844%
Returns for 5 years25.0450.1950%
Returns for 10 yearsN/A102.41-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATEX66.961.60
+2.45%
Anterix
FRAF56.63-0.39
-0.68%
Franklin Financial Services Corp
MNST88.24-0.86
-0.97%
Monster Beverage Corp
TFX125.24-2.33
-1.83%
Teleflex
VTGN0.58-0.07
-10.42%
VistaGen Therapeutics